Transconjunctival sutureless vitrectomy with tissue plasminogen activator, gas and intravitreal bevacizumab in the management of predominantly hemorrhagic age-related macular degeneration

QR Code

Transconjunctival sutureless vitrectomy with tissue plasminogen activator, gas and intravitreal bevacizumab in the management of predominantly hemorrhagic age-related macular degeneration

Luis Arias1,2, Jordi Mon&eacute;s11Institut de la M&agrave;cula i de la Retina, Centro M&eacute;dico Teknon, Barcelona; 2Hospital Universitari de Bellvitge, L&rsquo;Hospitalet de Llobregat, BarcelonaPurpose: To determine the efficacy and safety of treating predominant...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Luis Arias, Jordi Mon&eacute;s
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2010
Sujets:	Ophthalmology RE1-994
Accès en ligne:	https://doaj.org/article/b7d3fceb56d244fea27dc88ec79a3637
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Learning curve of sutureless transconjunctival 20-gauge vitrectomy
par: Simanjuntak GWS, et autres
Publié: (2014)

Bacterial endophthalmitis following 25-gauge transconjunctival sutureless vitrectomy
par: Drew N Sommerville, et autres
Publié: (2008)

Sympathetic ophthalmia after 23-gauge transconjunctival sutureless vitrectomy
par: Masatoshi Haruta, et autres
Publié: (2010)

Long-term outcomes of intravitreous bevacizumab or tissue plasminogen activator or vitrectomy for macular edema due to branch retinal vein occlusion
par: Kumagai K, et autres
Publié: (2019)

Outcome of 20-gauge transconjunctival cannulated sutureless vitrectomy using silicone oil or air tamponade
par: Mohamed AA, et autres
Publié: (2013)

Tissue plasminogen activator (tPA) in the management of predominantly hemorrhagic age-related macular degeneration, milligram/milliliter or microgram/milliliter?
par: Boone NW, et autres
Publié: (2012)

Factors influencing self-sealing of sclerotomy performed under gas tamponade in 23-gauge transconjunctival sutureless vitrectomy
par: Takashina H, et autres
Publié: (2014)

Hemiretinal vein occlusion with macular hemorrhage and edema treated with intravitreal bevacizumab
par: Yalamanchi S, et autres
Publié: (2011)

Segmentation and removal of fibrovascular membranes with high-speed 23 G transconjunctival sutureless vitrectomy, in severe proliferative diabetic retinopathy
par: Celik E, et autres
Publié: (2016)

Unexplained postoperative retinal hemorrhage after 23-gauge sutureless vitrectomy
par: Ohno H, et autres
Publié: (2011)

Investigation of postoperative intraocular pressure in cases of silicone oil removal using 25-gauge transconjunctival sutureless vitrectomy with oblique incisions
par: Takashina H, et autres
Publié: (2015)

Transconjunctival 25-gauge pars plana vitrectomy and internal limiting membrane peeling for chronic macular edema
par: Cho M, et autres
Publié: (2012)

Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
par: Juan Carlos Mesa Guti&eacute;rrez, et autres
Publié: (2008)

Displacement of submacular hemorrhage associated with age-related macular degeneration using vitrectomy and submacular tPA injection followed by intravitreal ranibizumab
par: Sukhpal Singh Sandhu, et autres
Publié: (2010)

Intravitreal bevacizumab as an adjunctive therapy before diabetic vitrectomy
par: Ashraf M El-Batarny
Publié: (2009)

Combined treatment of exudative age related macular degeneration with photodynamic therapy and intravitreal triamcinolone
par: Jos&eacute; M&ordf; Ruiz-Moreno, et autres
Publié: (2008)

Is monthly retreatment with intravitreal bevacizumab (Avastin&reg;) necessary in neovascular age-related macular degeneration?
par: Nicola G Ghazi, et autres
Publié: (2010)

Long-Term Outcome of Eyes with Vitrectomy for Submacular and/or Vitreous Hemorrhage in Neovascular Age-Related Macular Degeneration
par: Setsuko Kawakami, et autres
Publié: (2021)

Combined intravitreal bevacizumab and photodynamic therapy with vertiporfin for management of choroidal neovascularization secondary to age-related macular degeneration
par: Mamdouh M Kabeel, et autres
Publié: (2008)

The effect of intravitreal bevacizumab (Avastin&reg;) on ocular pulse amplitude in neovascular age-related macular degeneration
par: Ehud Rechtman, et autres
Publié: (2011)

Intravitreal bevacizumab has initial clinical benefit lasting eight weeks in eyes with neovascular age-related macular degeneration
par: P William Conrad, et autres
Publié: (2008)

Systemic adverse events after intravitreal bevacizumab versus ranibizumab for age-related macular degeneration: a meta-analysis.
par: Wei Wang, et autres
Publié: (2014)

Effect of intravitreal bevacizumab on diabetic macular edema with hard exudates
par: Jeon S, et autres
Publié: (2014)

Different techniques of transconjunctival cannulated vitrectomy versus conventional non-cannulated vitrectomy in various vitreoretinal disorders
par: Ghoraba HH, et autres
Publié: (2013)

Location of submacular hemorrhage as a predictor of visual outcome after intravitreal ranibizumab for age-related macular degeneration
par: Karagiannis D, et autres
Publié: (2017)

Intravitreal ranibizumab for symptomatic drusenoid pigment epithelial detachment without choroidal neovascularization in age-related macular degeneration
par: Roberto Gallego-Pinazo, et autres
Publié: (2011)

Intravitreal Tissue Plasminogen Activator Injection for Treatment-Resistant Diabetic Macular Edema of the Vitrectomized Eye
par: Ren Aoki, et autres
Publié: (2021)

A matched-control comparison of serious adverse events after intravitreal injections of bevacizumab for age-related macular degeneration and cataract extraction
par: Fischer N, et autres
Publié: (2013)

Pneumatic displacement with intravitreal bevacizumab for massive submacular hemorrhage due to polypoidal choroidal vasculopathy
par: Kitahashi M, et autres
Publié: (2014)

Skin rash associated with intravitreal bevacizumab in a patient with macular choroidal neovascularization
par: Ioannis D Ladas, et autres
Publié: (2008)

Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?
par: Dimitrios A Karagiannis, et autres
Publié: (2009)

Short-Term Outcomes After COVID-19-Related Treatment Interruption Among Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Bevacizumab
par: Allegrini D, et autres
Publié: (2021)

The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions
par: Ivanovska Adjievska B, et autres
Publié: (2017)

Effect of initial retinal thickness on outcome of intravitreal bevacizumab therapy for diabetic macular edema
par: Mushtaq B, et autres
Publié: (2014)

Intravitreal bevacizumab alone or combined with triamcinolone acetonide as the primary treatment for diabetic macular edema
par: Marey HM, et autres
Publié: (2011)

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
par: Pessoa B, et autres
Publié: (2021)

Intravitreal bevacizumab in macular edema secondary to branch retinal vein occlusion: 12-month results
par: Thapa R, et autres
Publié: (2012)

Intravitreal bevacizumab for macular edema due to branch retinal vein occlusion: 12-month results
par: Demir M, et autres
Publié: (2011)

Intravitreal bevacizumab injections for diabetic macular edema – predictors of response: a retrospective study
par: Joshi L, et autres
Publié: (2016)

Grid photocoagulation combined with intravitreal bevacizumab for recurrent macular edema associated with retinal vein occlusion
par: Ogino K, et autres
Publié: (2011)